Gilead increases 2024 outlook, expects new drug filing by end of year

By Yahoo! Finance | Nov 7, 2024 at 12:58 PM EST

Gilead Sciences raised its growth forecast for the year after strong Q3 results, shifting focus from COVID revenues. CEO Daniel O'Day highlighted the company's best quarter, with increased sales in HIV and new business areas like oncology and inflammation. The stock rose 6% on the news.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.